Metallotherapeutic complexes with high selective properties for anti-neoplastic therapy

It is one of the challenging works to deal with second major cause of death due to cancer and to reduce the mortality rate caused by this. Researchers have been finding various approaches to minimise the unwanted effect of cancer therapy and increase the selectivity of the cancer cells that are cancerous without harming the normal cells. Accordingly, they have discovered and reported a series of anti-cancer complexes with moderate to high selective behaviour. Conventional cancer therapies are resistant to some of standard drugs. When we consider the group of metallotherapeutic anticancer agents, platinum (Pt) based anti-neoplastic complexes have some drawbacks and lower potency and selectivity than complexes like Ruthenium (Ru), Iridium (Ir), Rhodium (Rh) and Rhenium (Re) towards various cancer cell lines (in vitro). Many of them have proved the in vivo applications. This review aims to provide a comprehensive summary of prior literature pertaining to the cytotoxic impact and cellular uptake of those metallocomplexes (Ru, Ir, Rh and Re), with particular emphasis on recently developed metal-based complexes. Most of them target the DNA, mitochondria, and induces cancer cell apoptosis lowering the adverse drug reaction.

Automated summary

This article reviews the literature on the cytotoxic effects and cellular uptake of metal complexes such as ruthenium, iridium, rhodium, and rhenium, with a particular focus on recently developed metal-based complexes. These complexes primarily target DNA and mitochondria, inducing cancer cell apoptosis to reduce adverse drug reactions.